Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) vs Finasteride (topical): Bimatoprost (lashes) has the stronger overall evidence (8 vs 6.5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Bimatoprost (lashes) and Finasteride (topical) have evidence — compare verdict strength side-by-side.
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Apply finasteride 0.25% topical solution to the scalp once daily. Lower applied volumes reduce serum DHT less while still cutting scalp DHT substantially.
evening
Finasteride 0.25% topical solution
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
immediate
24 weeks
24 weeks
1 week
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
J Eur Acad Dermatol Venereol (2022) · Rct · n=458
The pivotal trial: phase III, double-blind, DOUBLE-DUMMY, so it compares topical against placebo AND against oral finasteride in the same study.
Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia
Int J Clin Pharmacol Ther (2016) · Rct · n=50
⚠️ THE CAVEAT THAT MATTERS: serum DHT fell 60-70%. "Topical avoids systemic exposure" is not what this study shows at the higher doses.
Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia
Indian J Dermatol Venereol Leprol (2009) · Rct · n=45
A direct head-to-head of gel against tablet, double-blind and double-dummy, six months.
Bimatoprost (lashes) has a higher evidence score (8/10 vs 6.5/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Finasteride (topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.